REDWOOD CITY, Calif., Dec. 19, 2014 /PRNewswire/ -- Bina Technologies, Inc.
Teva Announces FDA Approval of QNASL® (Beclomethasone Dipropionate) Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis
Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union
Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer
Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology
INDIANAPOLIS and LYON, France, Dec.
ABBOTT PARK, Ill., Dec. 18, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 33rd Annual J.P.
14 Indicted in Connection with New England Compounding Center and Nationwide Fungal Meningitis Outbreak
Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer
THOUSAND OAKS, Calif., Dec.
UCB, Advent International and Avista Capital Partners mutually agree to terminate acquisition agreement for Kremers Urban
Salix Pharmaceuticals Provides Updates on Wholesaler Inventory Reductions and the XIFAXAN® 550 for IBS-D Approval Timeline, and Provides Preliminary Guidance for 2015 and 2016
Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition
Editor Note: For more information about this release, please scroll to bottom.
LONDON, December 15, 2014